Your browser doesn't support javascript.
loading
Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
Suzuki, Kotaro; Shiraishi, Yusuke; Furukawa, Junya; Okamura, Yasuyoshi; Bando, Yukari; Hara, Takuto; Okada, Keisuke; Terakawa, Tomoaki; Hyodo, Yoji; Chiba, Koji; Teishima, Jun; Nakano, Yuzo; Miyake, Hideaki.
Afiliación
  • Suzuki K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Electronic address: pikataro1012@gmail.com.
  • Shiraishi Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Furukawa J; Department of Urology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Okamura Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Bando Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Hara T; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Okada K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Terakawa T; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Hyodo Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Chiba K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Teishima J; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Nakano Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Miyake H; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
Clin Genitourin Cancer ; 22(5): 102140, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39018723
ABSTRACT

BACKGROUND:

Optimal drug selection for metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear. We therefore assessed the clinical outcomes of mHSPC treated with new-generation androgen receptor pathway inhibitors (ARSIs) and identified risk factors associated with the prognosis of mHSPC.

METHODS:

We retrospectively reviewed 324 patients with mHSPC who were treated with ARSIs, including abiraterone acetate, enzalutamide, and apalutamide, between January 2018 and December 2022. In addition to assessing the prostate-specific antigen (PSA) response and overall survival (OS) during ARSI treatment, we investigated several potential risk factors for a poor OS in patients with mHSPC.

RESULTS:

Patients with a ≥ 90% PSA reduction (hazard ratio [HR] 0.24, 95% confidence interval [CI], 0.10-0.58; P = .002) and those whose PSA declined to ≤ 0.2 ng/mL (HR 0.22, 95% CI, 0.08-0.63; P = .005) showed significantly better OS than other patients. Gleason grade group 5 (GG5), presence of liver metastasis, and an LDH ≥ 250 U/L were identified as prognostic factors significantly associated with a poor OS, with HRs of 2.31 (95% CI, 1.02-5.20; P = .044), 7.87 (95% CI, 2.61-23.8; P < .001) and 3.21 (95% CI, 1.43-7.23; P = .005).

CONCLUSION:

We identified GG5, the presence of liver metastasis, and elevated LDH at the diagnosis as significant factors predicting the OS of mHSPC, but the choice of ARSIs did not affect the prognosis. The potential prognostic impact of these markers requires further investigation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feniltiohidantoína / Neoplasias de la Próstata / Tiohidantoínas / Benzamidas / Antígeno Prostático Específico / Antagonistas de Receptores Androgénicos / Acetato de Abiraterona / Nitrilos Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Feniltiohidantoína / Neoplasias de la Próstata / Tiohidantoínas / Benzamidas / Antígeno Prostático Específico / Antagonistas de Receptores Androgénicos / Acetato de Abiraterona / Nitrilos Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos